Gastric Cancer (GASC)
Gastric cancer (GASC) is a complex disease with various molecular targets and therapeutic approaches. The pathogenesis of gastric cancer is a complex process involving multiple genetic and environmental factors. Our company is a leading provider of drug and therapy development services in the field of gastric cancer (GASC).
Introduction to Gastric Cancer (GASC)
Gastric Cancer (GASC), also known as stomach cancer, is a malignancy that develops in the stomach lining. The annual incidence of new gastric cancer is 6.9 per 100,000 men and women. Gastric Cancer arises from the epithelial cells lining the stomach and can spread to nearby lymph nodes and other organs.
- Classification of Gastric Cancer: Conventional Gastric Cancer, Early-Onset Gastric Cancer, Gastric Stump Cancer, and Hereditary Diffuse Gastric Cancer
- Risk Factors of Gastric Cancer: Smoking, Alcohol, Diet, Genetics, Heavy metals, and Diabetes
Fig.1 Onsets of gastric cancer development. (Machlowska, Julita, et al., 2020)Molecular Biomarkers of Gastric Cancer (GASC)
Molecular biomarkers play a crucial role in the development of diagnostics for gastric cancer. Biomarkers involved in gastric cancer include:
- HER2
- p53
- PD1
- p73
- mdm2
- Bcl-2
- pRb
- CCND1
- p16
- p27Kip1
- MUC
- MRP2
- MDR1
- GST-P
- MSI
Targeted Therapy Development of GASC
Claudin 18.2 (CLDN18.2)
CLDN18.2 is a protein specifically expressed in gastric mucosa and has shown potential as a therapeutic target. Monoclonal antibodies like zolbetuximab, which specifically target CLDN18.2, have demonstrated improved survival outcomes in CLDN18.2-positive gastric cancer cases.
Fibroblast Growth Factor Receptors (FGFRs)
Alterations in FGFRs, such as mutations and amplifications, are common in gastric cancer. Selective FGFR inhibitors, including bemarituzumab, have shown promise in treating gastric cancer with FGFR2 amplifications.
Epidermal Growth Factor Receptor (EGFR)
EGFR is another potential target for gastric cancer therapy, particularly in cases with EGFR amplifications or overexpression. Patient selection based on EGFR expression levels is crucial for the success of EGFR-targeted therapies.
MET/HGF Pathway
The MET/HGF pathway, involving the c-MET receptor and hepatocyte growth factor (HGF), has been targeted in gastric cancer therapy. While early studies have not shown significant benefits, further research is ongoing to explore the potential of c-MET inhibitors.
Fig.2 Therapy of gastric cancer. (Wen-Long Guan, et al., 2023)Our Services
At our company, we are at the forefront of gastric cancer drug and therapy development services. Through our expertise in biomarker identification, diagnostics development, and targeted therapy development, we strive to advance the field and accelerate the development of gastric cancer therapies for the global pharmaceutical industry.
Therapy Development Platforms
Animal Models of Gastric Cancer
Animal models play a crucial role in preclinical research for gastric cancer therapy. We have established expertise in developing and utilizing relevant animal models that closely mimic the disease characteristics and response to therapy. These models enable us to evaluate the safety and efficacy of potential therapies.
| Chemical Carcinogenesis Models | |||
|---|---|---|---|
| Chemical carcinogenesis models involve the induction of gastric cancer through the administration of specific chemicals or carcinogens. By employing precise dosing regimens and monitoring the animals' health, our company ensures the accurate replication of chemical carcinogenesis models. | |||
| Optional Models | N-methyl-N-nitrosourea (MNU) Induced Model | ||
| Helicobacter Infection Models | |||
| Helicobacter pylori infection is a well-established risk factor for gastric cancer. To investigate the interplay between H. pylori infection and gastric carcinogenesis, we rely on animal models that mimic the infection process and its effects on the gastric mucosa. | |||
| Genetically Engineered Models | |||
| At our company, we specialize in developing genetically engineered models for gastric cancer research. Our expertise in genetic engineering techniques, such as CRISPR/Cas9 technology, allows us to generate accurate and reliable models that recapitulate the genetic alterations observed in human gastric cancer. | |||
| Optional Models |
|
|
|
| Optional Species | Mice, Rats, Others | ||
In addition to these models, our comprehensive services encompass other models that target specific signaling pathways, tumor suppressor genes, and molecular targets. These models have provided valuable insights into the role of the TGF-β/Smad signaling pathway in gastric cancer development and the significance of CDH1 loss in diffuse-type gastric cancer.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Machlowska, Julita, et al. "Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies." International journal of molecular sciences 21.11 (2020): 4012.
- Guan, Wen-Long, Ye He, and Rui-Hua Xu. "Gastric cancer treatment: recent progress and future perspectives." Journal of hematology & oncology 16.1 (2023): 57.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
